ProfileGDS5678 / 1450660_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 82% 84% 83% 84% 82% 83% 83% 82% 80% 82% 82% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8507782
GSM967853U87-EV human glioblastoma xenograft - Control 25.8847681
GSM967854U87-EV human glioblastoma xenograft - Control 35.8865282
GSM967855U87-EV human glioblastoma xenograft - Control 46.4104484
GSM967856U87-EV human glioblastoma xenograft - Control 56.0861883
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.9945984
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8450282
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0068583
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.091783
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.9110282
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6663180
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9999382
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.9711782
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7422381